Dozens of widely prescribed medications, from cancer chemotherapy agents to common antibiotics and psychiatric drugs, can injure the heart in ways ranging from subtle changes in pumping strength to sudden fatal arrhythmias. The damage is not limited to a single mechanism: some drugs poison heart-muscle cells directly, others disrupt the heart’s electrical rhythm, and still others raise blood pressure or promote blood clots. Understanding which drug classes carry cardiac risk, how the damage happens, and what can be done to catch it early matters whether you are a cancer patient weighing treatment options, someone taking a daily psychiatric medication, or just someone handed a prescription for a common antibiotic.
Anthracyclines and Direct Heart-Muscle Damage
Anthracyclines, a class of chemotherapy drugs that includes doxorubicin, epirubicin, and daunorubicin, are among the most effective cancer treatments ever developed and also among the most cardiotoxic. They work against tumors by targeting an enzyme called topoisomerase 2α, which cancer cells need to copy their DNA. The problem is that heart-muscle cells express a related enzyme, topoisomerase 2β, and anthracyclines hit that target too. Research has shown that when topoisomerase 2β is genetically deleted from heart cells in animal models, anthracycline-induced DNA damage, oxidative stress, and heart failure are all prevented, pinpointing it as the key mediator of the cardiac injury.1PubMed Central. ANTHRACYCLINE-INDUCED CARDIOTOXICITY: MECHANISM AND PREVENTION
The damage from anthracyclines builds with each dose. A retrospective analysis of three clinical trials estimated that roughly a quarter of patients would develop heart failure by the time they reached a cumulative doxorubicin dose of 550 mg/m².2PubMed. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials For years, clinicians treated doses below 450 mg/m² as relatively safe, but that view has shifted. Evidence now shows that subclinical cardiac changes, meaning measurable declines in heart function that the patient may not yet feel, occur even at doses once considered harmless.3PubMed Central. Beyond Expectations: A Case of Doxorubicin-Induced Cardiomyopathy at a Remarkably Low Cumulative Dose This dose-dependent toxicity is a major reason anthracycline use comes with lifetime cumulative dose limits, and why some patients develop heart failure years or even decades after treatment ends.4Biomedicine & Pharmacotherapy. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management
HER2-Targeted Therapies and a Different Pattern of Injury
Trastuzumab, a targeted therapy used widely in HER2-positive breast cancer, also carries cardiac risk, but the pattern looks different from what anthracyclines do. Trastuzumab blocks a receptor called ERBB2 on the surface of cancer cells. Heart cells use that same receptor to maintain their health and respond to stress, so blocking it leaves the heart more vulnerable. Importantly, the damage from trastuzumab is not cumulative and not dose-related the way anthracycline injury is. Patients who develop heart problems on trastuzumab generally improve once the drug is stopped.5Mayo Clinic Proceedings. Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads
The complication is that many patients receive trastuzumab after having already been treated with anthracyclines, and prior anthracycline exposure increases the number of surface receptors that trastuzumab subsequently blocks. That sequential combination ratchets up the risk. Clinicians now monitor heart function closely during and after trastuzumab treatment, and the reversibility of the injury gives them more flexibility to pause and restart therapy when needed.
Immune Checkpoint Inhibitors and Myocarditis
Checkpoint inhibitors like nivolumab, pembrolizumab, and ipilimumab have transformed cancer care by unleashing the immune system against tumors. The trade-off is that an unleashed immune system can also attack healthy tissues, including the heart. Immune-related myocarditis, an inflammation of the heart muscle, is uncommon with these drugs but extremely dangerous when it occurs. Mortality rates in severe cases run between about 38% and 46%.6PubMed Central. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
Diagnosing checkpoint-inhibitor myocarditis is tricky because it tends to appear shortly after treatment begins and can mimic other conditions. Symptoms like fatigue, chest pain, and shortness of breath overlap with many things a cancer patient might experience. Blood tests, imaging, and sometimes cardiac biopsy are needed to confirm it. Because the condition can deteriorate rapidly, oncologists are trained to have a high index of suspicion in any patient newly started on checkpoint immunotherapy who develops unexplained cardiac symptoms.
VEGF Inhibitors and Blood Pressure
A different class of cancer drugs targets the signaling pathway that tumors use to grow new blood vessels, called the VEGF pathway. Drugs like sunitinib, sorafenib, and bevacizumab are effective at starving tumors of blood supply, but the VEGF pathway also plays a role in keeping normal blood vessels relaxed and healthy. When these drugs suppress that pathway, nitric oxide production drops, blood vessels constrict, and blood pressure rises. On top of that, the drugs can reduce the density of tiny blood vessels throughout the body, which further drives up vascular resistance.7PubMed Central. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors
The resulting hypertension is not a minor side effect. Sustained high blood pressure damages the heart over time and can lead to heart failure, especially in patients who already have cardiovascular risk factors. Managing blood pressure aggressively during treatment with VEGF inhibitors is now considered a standard part of care, and the development of hypertension is actually monitored as a near-universal expected event rather than a surprise complication.
Psychiatric Medications and Electrical Disturbances
Several classes of psychiatric drugs can interfere with the heart’s electrical system, specifically by blocking a potassium channel in heart cells known as hERG. This channel helps heart cells reset their electrical charge after each beat, and when it is blocked, the interval between beats stretches out in a way that shows up on an electrocardiogram as QT prolongation. A prolonged QT interval sets the stage for a dangerous rhythm called torsades de pointes, which can degenerate into cardiac arrest.
Many antipsychotic drugs block the hERG channel to varying degrees.8PubMed. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs Antidepressants share this risk: amitriptyline, one of the older tricyclic antidepressants, has long been known to cause QT prolongation and torsades de pointes through hERG channel blockade.9PubMed Central. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline Systematic reviews confirm that QT prolongation is one of the main unwanted cardiac effects across both antipsychotic and antidepressant drug classes, driven primarily by hERG channel interference.10PubMed. Impact of antipsychotics and antidepressants drugs on long QT syndrome induction related to hERG channel dysfunction: A systematic review The risk is higher when patients take more than one QT-prolonging drug at the same time, have low potassium or magnesium levels, or have pre-existing heart conditions. Baseline and periodic electrocardiograms are often recommended for patients on higher-risk psychiatric medications.
Clozapine and Myocarditis
Clozapine, an antipsychotic reserved for treatment-resistant schizophrenia, carries a distinct cardiac risk beyond QT prolongation: it can trigger myocarditis, an inflammation of the heart muscle. An analysis of electronic health records found that all confirmed cases of clozapine-induced myocarditis occurred within the first 42 days of starting the drug, with the average diagnosis around day 17.11PubMed Central. Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy Every identified case was in a patient either being started on clozapine for the first time or restarted after a very short prior course that ended due to side effects. The tight window means that after about six weeks of treatment, the risk of this particular complication drops substantially and monitoring can be adjusted accordingly.
Stimulants and Cardiovascular Strain
Prescription stimulants like amphetamines, used for attention-deficit disorders, and their illicit cousins produce cardiovascular stress by flooding the body with norepinephrine, dopamine, and serotonin. The results include blood-vessel constriction, rapid heart rate, and an increased propensity for abnormal heart rhythms. In susceptible individuals, stimulants can trigger coronary artery spasm, cutting off blood flow to part of the heart even in arteries that have no plaque buildup.12International Journal of Clinical Cardiology. A Case of Coronary Artery Spasm Associated with Lisdexamfetamine Use For most people taking therapeutic doses under medical supervision, the absolute risk remains low, but it rises with higher doses, co-use of other stimulants like caffeine or cocaine, and pre-existing heart conditions.
Common Antibiotics and Hidden Cardiac Risk
Perhaps the most surprising entries on the list of cardiotoxic drugs are certain everyday antibiotics. Azithromycin, one of the most commonly prescribed antibiotics worldwide, was linked in a large cohort study to a roughly threefold increase in the risk of cardiovascular death during a five-day course compared to patients who took no antibiotics. Compared to amoxicillin specifically, azithromycin carried about two and a half times the risk of cardiovascular death, translating to an estimated 47 additional cardiovascular deaths per million courses in average-risk patients. In people with the highest cardiovascular risk, that number climbed to about 245 additional deaths per million courses.13PubMed Central. Azithromycin and the Risk of Cardiovascular Death
A separate population-level study from Taiwan corroborated those findings and extended them to fluoroquinolone antibiotics. Compared to amoxicillin-clavulanate, azithromycin carried over a fourfold increase in the odds of ventricular arrhythmia, and moxifloxacin carried about a threefold increase. Levofloxacin showed a smaller, non-significant increase in arrhythmia risk but still had a nearly twofold increase in cardiovascular death.14Clinical Infectious Diseases. Risks of Cardiac Arrhythmia and Mortality Among Patients Using New-Generation Macrolides, Fluoroquinolones, and β-Lactam/β-Lactamase Inhibitors: A Taiwanese Nationwide Study These antibiotics, like the psychiatric drugs discussed above, can prolong the QT interval. The risk is highest in people who already have heart disease, electrolyte imbalances, or who are taking other QT-prolonging medications. For a healthy young adult given a short course of azithromycin for bronchitis, the absolute risk remains very small. For an older adult with existing heart problems, the choice of antibiotic may matter more than most patients realize.
NSAIDs and Cardiovascular Events
Nonsteroidal anti-inflammatory drugs, the class that includes ibuprofen, naproxen, and the prescription COX-2 inhibitors like celecoxib, are among the most widely used medications on earth. Their cardiac risks came into sharp focus when rofecoxib (Vioxx) was pulled from the market in 2004 due to excess heart attacks and strokes. The underlying mechanism involves suppression of COX-2, an enzyme whose products play roles in keeping blood pressure in check, maintaining kidney blood flow, and preventing blood clots from forming in arteries. Blocking COX-2 tips the balance toward higher blood pressure, sodium retention, and a prothrombotic state that favors heart attacks and strokes.15PubMed Central. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective
The risk is not exclusive to prescription-strength COX-2 inhibitors. Over-the-counter ibuprofen and diclofenac carry measurable cardiovascular risk at higher doses and with prolonged use. Naproxen appears to have a somewhat lower cardiovascular risk profile than other NSAIDs, which is why it is sometimes preferred in patients with cardiac concerns, though it is not risk-free either. For anyone with existing heart disease, kidney problems, or uncontrolled blood pressure, even short-term NSAID use deserves a conversation with a doctor.
Antiarrhythmic Drugs That Cause Arrhythmias
One of the more counterintuitive entries in cardiotoxicity is the class of drugs designed specifically to treat irregular heart rhythms. Some antiarrhythmic medications can worsen the very arrhythmias they are intended to suppress, a phenomenon called proarrhythmia.16PubMed. Antiarrhythmic Drugs Class IC agents like flecainide and propafenone are particularly risky in patients with structural heart disease, meaning hearts already weakened or scarred by prior injury. In a study of patients with structural heart disease and implantable defibrillators, proarrhythmia was suspected in about 6% of those placed on class IC drugs, with those patients experiencing multiple recurrent dangerous rhythm events that required their defibrillator to fire.17PubMed Central. Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator This is why class IC antiarrhythmics are generally avoided in patients with prior heart attacks or weakened hearts, and why choosing the right rhythm-control drug requires careful assessment of underlying cardiac health.
Fenfluramine, Serotonin, and Heart Valve Damage
The diet-drug debacle of the 1990s, when the combination of fenfluramine and phentermine (“fen-phen”) was found to cause heart valve disease, revealed a mechanism that extends beyond a single banned drug. Fenfluramine and its active metabolite norfenfluramine activate a specific serotonin receptor on heart valves called 5-HTâ‚‚B. Research has shown that activation of this receptor is necessary to produce the kind of valve damage seen in fen-phen users, and that serotonergic drugs that do not activate 5-HTâ‚‚B receptors are unlikely to cause it.18PubMed. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications This finding prompted calls for all drugs with serotonergic activity to be screened for 5-HTâ‚‚B agonism. The same mechanism is behind the valve disease seen in carcinoid syndrome, where tumors secrete large amounts of serotonin. It serves as a reminder that drugs interacting with the serotonin system can affect the heart through unexpected pathways.
Diabetes Medications and Fluid Overload
Thiazolidinediones, a class of diabetes drugs that includes rosiglitazone and pioglitazone, improve insulin sensitivity but cause the body to retain fluid. That fluid retention can tip susceptible patients into congestive heart failure.19PubMed. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials The risk is especially concerning in patients with type 2 diabetes because they already have elevated rates of heart disease. Both rosiglitazone and pioglitazone carry black-box warnings about heart failure, and their use has declined significantly with the arrival of newer diabetes drugs that appear to be either neutral or actively protective for the heart.
Illicit Drugs and the Heart
Cocaine is one of the most thoroughly documented cardiotoxic substances outside of prescription medicine. It acts as a powerful sympathomimetic, flooding the cardiovascular system with signals that constrict blood vessels, speed the heart, and promote clotting. Acute use can trigger arrhythmias, angina, and heart attacks. Over time, chronic cocaine use leads to structural changes in the heart including increased thickness of the heart wall and reduced chamber volume, changes associated with heart failure.20PubMed Central. Cocaine and Cardiotoxicity: A Literature Review Treating cocaine-related chest pain is complicated by the fact that standard medications like beta-blockers, which are first-line in other forms of heart attack, were long thought to be harmful in cocaine users because of concerns about worsening vessel constriction. That view has evolved somewhat, but it illustrates how substance use can change the safety profile of otherwise routine cardiac treatments.
Catching the Damage Early
The traditional way to monitor for drug-induced heart damage is to track the heart’s ejection fraction, a measure of how much blood the left ventricle pumps out with each beat, using echocardiography. The problem is that ejection fraction is not very sensitive to early damage. By the time it drops noticeably, significant injury has already occurred. A more sensitive measure is global longitudinal strain, or GLS, which uses advanced echocardiographic techniques to detect subtle changes in how heart muscle fibers contract. Multiple studies have shown that a drop of about 10% to 15% in GLS during chemotherapy predicts later development of heart failure, often well before ejection fraction budges.21PubMed. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review22PubMed Central. Strain Imaging in Cardio-Oncology
Blood tests add another layer of early warning. Troponin, a protein released when heart cells are injured, and BNP or NT-proBNP, markers that rise when the heart is under strain, have both been shown to predict later heart failure in cancer patients undergoing cardiotoxic treatment.23PubMed Central. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity In one study, the median NT-proBNP level nearly doubled after just six weeks of chemotherapy, and close to half of the patients with elevated levels also showed worsening strain on their echocardiograms.24European Heart Journal. The integrated role of NT-pro BNP and STE-GLS for the early detection of chemotherapy-induced cardiotoxicity Combining blood biomarkers with strain imaging gives clinicians a much better chance of detecting damage before it becomes irreversible.
Protecting the Heart During Treatment
When a cardiotoxic drug is the best or only option against a life-threatening disease, the goal shifts from avoidance to mitigation. Several strategies have shown promise. A systematic review and meta-analysis of cardioprotective therapies found that giving preventive treatments alongside chemotherapy cut the rate of cardiac events by roughly two-thirds overall. Dexrazoxane, a drug specifically designed to protect the heart during anthracycline therapy, reduced cardiac events significantly, as did beta-blockers, statins, and drugs that block the angiotensin system (ACE inhibitors and related agents).25European Journal of Cancer. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
Dexrazoxane has been studied the most thoroughly. In Cochrane-reviewed trials, the rate of heart failure in patients who received dexrazoxane alongside anthracyclines was roughly 1.4%, compared to about 10% in patients who received anthracyclines alone.26PubMed Central. Cardioprotective strategies in the management of chemotherapy-induced cardiotoxicity: current approaches and future directions A separate meta-analysis confirmed that dexrazoxane, beta-blockers, and ACE inhibitors all helped preserve ejection fraction during anthracycline treatment.27PubMed. Prophylactic Agents for Preventing Cardiotoxicity Induced Following Anticancer Agents: A Systematic Review and Meta-Analysis of Clinical Trials Despite this evidence, dexrazoxane is still underused, partly because of early concerns (since addressed) that it might interfere with chemotherapy effectiveness. Current European Society of Cardiology cardio-oncology guidelines emphasize baseline risk assessment, active monitoring, and the use of cardioprotective agents when the risk warrants it.28PubMed Central. The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus
Who Is Most Vulnerable
Drug-induced cardiotoxicity does not hit everyone equally. People at the extremes of age are especially susceptible. Children’s hearts are still developing, making them particularly sensitive to agents like anthracyclines; childhood cancer survivors carry an elevated risk of heart problems that can emerge decades after their treatment ended. Older adults face a different problem: they are more likely to come to treatment with pre-existing risk factors like hypertension, diabetes, or coronary artery disease, which lower the threshold at which a cardiotoxic drug causes harm.29PubMed. Age-Related Considerations in Cardio-Oncology
Genetics also play a role that is only beginning to be understood. Pharmacogenomic studies have identified genetic variants that influence how the body processes certain drugs and how the heart responds to them. Some people carry variants in genes related to heart-muscle structure that may predispose them to drug-induced arrhythmias or cardiomyopathy, while others have variations in the enzymes that metabolize drugs, potentially leading to dangerously high drug levels even at standard doses.30PubMed. Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths The hope is that pharmacogenomic testing will eventually allow clinicians to identify high-risk individuals before treatment begins and tailor drug choices or doses accordingly.31PubMed Central. Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
The Rise of Cardio-Oncology as a Discipline
The growing recognition that modern cancer treatments carry significant cardiac risk has given rise to cardio-oncology, a subspecialty that sits at the intersection of cancer care and heart care. The field’s premise is that managing cardiotoxicity cannot be an afterthought. Patients need baseline cardiovascular risk assessment before they start treatment, active monitoring during it, and structured follow-up that extends well beyond the last dose of chemotherapy.32PubMed Central. Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice Without that framework, clinicians face an uncomfortable choice between giving suboptimal cancer treatment out of cardiac fear and giving optimal cancer treatment while hoping for the best with the heart. Cardio-oncology teams aim to eliminate that false dilemma by managing both risks simultaneously. While the field emerged from cancer care, the principles apply broadly: any time a necessary medication carries cardiac risk, the goal is to use it safely rather than avoid it at the cost of treating the disease it was prescribed for.